Diversity in antibody titer at an average of 87 days after the second dose of BNT162b2 mRNA coronavirus disease 2019 vaccine: data from a predominantly elderly population in a practice in Tokyo

  1. Yasuko Fuse-Nagase
  2. Mitsuo Nagase

Reviewed by

Read the full article See related articles

Discuss this preprint

Start a discussion What are Sciety discussions?

Listed in

Log in to save this article

Abstract

It is very important for the elderly, who tend to have serious COVID-19 infection and high mortality rates, to maintain sufficient immunity. We reviewed the medical charts of predominantly elderly population to obtain the data on serum anti-SARS-CoV-2S antibody titer after complete vaccination with the BNT162b2 mRNA vaccine (two doses) and evaluated the background factors associated with the titer. We enrolled 230 participants (101 men and 129 women). Their average age was 71.9 (SD 12.5) years, and median was 72 years. The anti-SARS-CoV-2S antibody titer varied from 0.55 U/mL to 4920 U/mL. We found that the value of the titer varied widely. The value of the titer was negatively associated with age, alcohol consumption, time elapsed from second vaccine dose, and use of immunosuppressive medication. The result that the titer was negatively associated with aging suggests that the timing of additional shot should be carefully determined especially among elderly population.

Article activity feed

  1. ScreenIT

    SciScore for 10.1101/2021.12.22.21268296: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    EthicsIRB: This study was approved by the ethics committee of Ibaraki University (N. 210300).
    Consent: Informed consent was obtained from all the participants in this study.
    Sex as a biological variablenot detected.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.

    Table 2: Resources

    Antibodies
    SentencesResources
    The participants of this study had no clinical history of COVID-19, had received both doses of the BNT162b2 mRNA vaccine in 2021, and were tested for serum anti-SARS-CoV-2S antibody titer at Nagase Clinic in Tokyo, Japan.
    anti-SARS-CoV-2S
    suggested: None
    Software and Algorithms
    SentencesResources
    Statistical Package for Social Sciences (SPSS, ver. 28) was used for statistical analyses; P < 0.05 was considered statistically significant.
    SPSS
    suggested: (SPSS, RRID:SCR_002865)

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
    Our study also has a limitation. We excluded participants who had a clinical history of COVID-19, but our study cohort could have included some asymptomatic cases as we neither measured antibody titers before the first vaccination dose nor performed PCR to rule out infection.

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    Results from scite Reference Check: We found no unreliable references.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  2. Version published to 10.1101/2021.12.22.21268296 on medRxiv